HT patch causes fewer breast changes than pill

Article

Transdermal hormone therapy causes fewer and less severe changes in breast density and less breast tenderness than oral HT, according to a study involving 202 postmenopausal women sponsored by Novartis.

Transdermal hormone therapy causes fewer and less severe changes in breast density and less breast tenderness than oral HT, according to a study involving 202 postmenopausal women sponsored by Novartis.

The two agents compared in the study were Estalis/Combipatch (Novartis, Basel, Switzerland) and Kliogest (Schering AG, Berlin, Germany).

The researchers found that mean breast density with the transdermal product was 38% versus 47% with the oral product (P<0.0001). Of the women using transdermal HT, 39% experienced no change in breast density versus 16% of the women using oral HT. Only 4% using the transdermal form had more than a 25% increase in density versus 16% of the women using the oral form. And 36% of the women in the transdermal group reported breast tenderness during the 1-year study versus 58% of the oral group (P=0.0002).

Recent Videos
Efficacy found from biopsychosocial approach to women’s sexual health | Image Credit: hermd.com.
Dr. Somi Javaid highlights disparities in sexual health | Image Credit: hermd.com.
How advancements in IVF are impacting embryologist workload and patient care | Image Credit: fertility.coopersurgical.com/our_experts
Study finds no causal link between maternal health in pregnancy and autism risk | Image Credit: med.nyu.edu/faculty.
Mirvie's RNA platform revolutionizes detection of fetal growth restriction | Image Credit: wexnermedical.osu.edu
How early genetic testing empowers parents and improves outcomes | Image Credit: tuftsmedicine.org
Dallas Reed highlights trends and barriers in prenatal genetic testing | Image Credit: tuftsmedicine.org
How maternal fetal medicine specialists improve outcomes for high-risk pregnancies | Image Credit: profiles.mountsinai.org
How the cobas liat assay panels improve STI detection | Image Credit: labqualityconfab.
Screening-to-diagnosis interval vital for gestational diabetes outcomes | Image Credit: ultracon2024.eventscribe.net
Related Content
© 2025 MJH Life Sciences

All rights reserved.